Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00693602 · ClinicalTrials.gov registry record · Phase 1
Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
NCT00693602 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 87 participants.
The verdict
NCT00693602, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
This is a compassionate use protocol for patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity or intolerance to E. coli L-asparaginase and/or PEG-L-asparaginase.
Interventions
- DRUG Erwinase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2006-06 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00693602
The ClinicalTrials.gov registry entry for NCT00693602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erwinase is the first listed.
NCT00693602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00693602 about?
NCT00693602 is a clinical study titled "Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma". This is a compassionate use protocol for patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity or intolerance to E. coli L-asparaginase and/or PEG-L-asparaginase.
What is the current status of trial NCT00693602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2006-06. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00693602?
The interventions under investigation include: Erwinase (DRUG).
Who is sponsoring clinical trial NCT00693602?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.